JACC:羟基氯喹可降低抗SSA/Ro阳性胎儿心脏传导阻滞发生率

2020-07-21 MedSci原创 MedSci原创

既往研究表明巨噬细胞Toll样受体信号在母体抗SSA/Ro介导的先天性心脏传导阻滞(CHB)中起重要作用。羟基氯喹(HCQ)是一种口服Toll样受体拮抗剂,广泛应用于包括妊娠期在内的狼疮患者,本研究目

既往研究表明巨噬细胞Toll样受体信号在母体抗SSA/Ro介导的先天性心脏传导阻滞(CHB)中起重要作用。羟基氯喹(HCQ)是一种口服Toll样受体拮抗剂,广泛应用于包括妊娠期在内的狼疮患者,本研究目的旨在评估HCQ对降低CHB的临床效果。

本研究纳入分析了54名抗SSA/Ro阳性伴CHB的孕妇,主要终点事件是孕期任何时候出现2度或3度CHB,次要终点事件是孤立性心内膜弹力纤维增生症,出生时1度CHB和皮疹。通过意向治疗(ITT)分析,54例接受了HCQ治疗的孕妇中有4例发生了主要终点事件。次要终点事件包括1例心内膜弹力纤维增生症和4例新生儿皮疹。

研究结果显示,羟基氯喹可以明显降低母体抗SSA/Ro介导的先天性心脏传导阻滞复发率,建议该药应用于二级预防抗SSA/Ro阳性的孕妇的胎儿心脏病。

原始出处:

Peter I et al.Hydroxychloroquine to Prevent Recurrent Congenital Heart Block in Fetuses of Anti-SSA/Ro-Positive Mothers.JACC.2020 July.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2033952, encodeId=dbce203395220, content=<a href='/topic/show?id=0edb25862cb' target=_blank style='color:#2F92EE;'>#传导阻滞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25862, encryptionId=0edb25862cb, topicName=传导阻滞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98e185, createdName=psybestwish, createdTime=Thu Apr 22 11:51:46 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854840, encodeId=96ac18548409b, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon May 03 04:51:46 CST 2021, time=2021-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069776, encodeId=0c6d2069e7655, content=<a href='/topic/show?id=e2628000e9f' target=_blank style='color:#2F92EE;'>#羟基氯喹#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80007, encryptionId=e2628000e9f, topicName=羟基氯喹)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2978132, createdName=minzju5052, createdTime=Tue Jul 21 20:51:46 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826616, encodeId=69b418266168c, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sun Mar 28 21:51:46 CST 2021, time=2021-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326688, encodeId=034f1326688f6, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Jul 23 02:51:46 CST 2020, time=2020-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803699, encodeId=816780369993, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4f25401928, createdName=ms8000000430368165, createdTime=Tue Jul 21 16:03:29 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803677, encodeId=1d7a8036e738, content=学到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec885401888, createdName=moira11, createdTime=Tue Jul 21 13:51:07 CST 2020, time=2020-07-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2033952, encodeId=dbce203395220, content=<a href='/topic/show?id=0edb25862cb' target=_blank style='color:#2F92EE;'>#传导阻滞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25862, encryptionId=0edb25862cb, topicName=传导阻滞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98e185, createdName=psybestwish, createdTime=Thu Apr 22 11:51:46 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854840, encodeId=96ac18548409b, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon May 03 04:51:46 CST 2021, time=2021-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069776, encodeId=0c6d2069e7655, content=<a href='/topic/show?id=e2628000e9f' target=_blank style='color:#2F92EE;'>#羟基氯喹#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80007, encryptionId=e2628000e9f, topicName=羟基氯喹)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2978132, createdName=minzju5052, createdTime=Tue Jul 21 20:51:46 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826616, encodeId=69b418266168c, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sun Mar 28 21:51:46 CST 2021, time=2021-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326688, encodeId=034f1326688f6, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Jul 23 02:51:46 CST 2020, time=2020-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803699, encodeId=816780369993, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4f25401928, createdName=ms8000000430368165, createdTime=Tue Jul 21 16:03:29 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803677, encodeId=1d7a8036e738, content=学到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec885401888, createdName=moira11, createdTime=Tue Jul 21 13:51:07 CST 2020, time=2020-07-21, status=1, ipAttribution=)]
    2021-05-03 hbwxf
  3. [GetPortalCommentsPageByObjectIdResponse(id=2033952, encodeId=dbce203395220, content=<a href='/topic/show?id=0edb25862cb' target=_blank style='color:#2F92EE;'>#传导阻滞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25862, encryptionId=0edb25862cb, topicName=传导阻滞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98e185, createdName=psybestwish, createdTime=Thu Apr 22 11:51:46 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854840, encodeId=96ac18548409b, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon May 03 04:51:46 CST 2021, time=2021-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069776, encodeId=0c6d2069e7655, content=<a href='/topic/show?id=e2628000e9f' target=_blank style='color:#2F92EE;'>#羟基氯喹#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80007, encryptionId=e2628000e9f, topicName=羟基氯喹)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2978132, createdName=minzju5052, createdTime=Tue Jul 21 20:51:46 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826616, encodeId=69b418266168c, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sun Mar 28 21:51:46 CST 2021, time=2021-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326688, encodeId=034f1326688f6, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Jul 23 02:51:46 CST 2020, time=2020-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803699, encodeId=816780369993, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4f25401928, createdName=ms8000000430368165, createdTime=Tue Jul 21 16:03:29 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803677, encodeId=1d7a8036e738, content=学到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec885401888, createdName=moira11, createdTime=Tue Jul 21 13:51:07 CST 2020, time=2020-07-21, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2033952, encodeId=dbce203395220, content=<a href='/topic/show?id=0edb25862cb' target=_blank style='color:#2F92EE;'>#传导阻滞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25862, encryptionId=0edb25862cb, topicName=传导阻滞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98e185, createdName=psybestwish, createdTime=Thu Apr 22 11:51:46 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854840, encodeId=96ac18548409b, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon May 03 04:51:46 CST 2021, time=2021-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069776, encodeId=0c6d2069e7655, content=<a href='/topic/show?id=e2628000e9f' target=_blank style='color:#2F92EE;'>#羟基氯喹#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80007, encryptionId=e2628000e9f, topicName=羟基氯喹)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2978132, createdName=minzju5052, createdTime=Tue Jul 21 20:51:46 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826616, encodeId=69b418266168c, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sun Mar 28 21:51:46 CST 2021, time=2021-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326688, encodeId=034f1326688f6, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Jul 23 02:51:46 CST 2020, time=2020-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803699, encodeId=816780369993, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4f25401928, createdName=ms8000000430368165, createdTime=Tue Jul 21 16:03:29 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803677, encodeId=1d7a8036e738, content=学到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec885401888, createdName=moira11, createdTime=Tue Jul 21 13:51:07 CST 2020, time=2020-07-21, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2033952, encodeId=dbce203395220, content=<a href='/topic/show?id=0edb25862cb' target=_blank style='color:#2F92EE;'>#传导阻滞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25862, encryptionId=0edb25862cb, topicName=传导阻滞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98e185, createdName=psybestwish, createdTime=Thu Apr 22 11:51:46 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854840, encodeId=96ac18548409b, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon May 03 04:51:46 CST 2021, time=2021-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069776, encodeId=0c6d2069e7655, content=<a href='/topic/show?id=e2628000e9f' target=_blank style='color:#2F92EE;'>#羟基氯喹#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80007, encryptionId=e2628000e9f, topicName=羟基氯喹)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2978132, createdName=minzju5052, createdTime=Tue Jul 21 20:51:46 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826616, encodeId=69b418266168c, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sun Mar 28 21:51:46 CST 2021, time=2021-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326688, encodeId=034f1326688f6, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Jul 23 02:51:46 CST 2020, time=2020-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803699, encodeId=816780369993, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4f25401928, createdName=ms8000000430368165, createdTime=Tue Jul 21 16:03:29 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803677, encodeId=1d7a8036e738, content=学到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec885401888, createdName=moira11, createdTime=Tue Jul 21 13:51:07 CST 2020, time=2020-07-21, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2033952, encodeId=dbce203395220, content=<a href='/topic/show?id=0edb25862cb' target=_blank style='color:#2F92EE;'>#传导阻滞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25862, encryptionId=0edb25862cb, topicName=传导阻滞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98e185, createdName=psybestwish, createdTime=Thu Apr 22 11:51:46 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854840, encodeId=96ac18548409b, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon May 03 04:51:46 CST 2021, time=2021-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069776, encodeId=0c6d2069e7655, content=<a href='/topic/show?id=e2628000e9f' target=_blank style='color:#2F92EE;'>#羟基氯喹#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80007, encryptionId=e2628000e9f, topicName=羟基氯喹)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2978132, createdName=minzju5052, createdTime=Tue Jul 21 20:51:46 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826616, encodeId=69b418266168c, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sun Mar 28 21:51:46 CST 2021, time=2021-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326688, encodeId=034f1326688f6, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Jul 23 02:51:46 CST 2020, time=2020-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803699, encodeId=816780369993, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4f25401928, createdName=ms8000000430368165, createdTime=Tue Jul 21 16:03:29 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803677, encodeId=1d7a8036e738, content=学到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec885401888, createdName=moira11, createdTime=Tue Jul 21 13:51:07 CST 2020, time=2020-07-21, status=1, ipAttribution=)]
    2020-07-21 ms8000000430368165

    学习

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2033952, encodeId=dbce203395220, content=<a href='/topic/show?id=0edb25862cb' target=_blank style='color:#2F92EE;'>#传导阻滞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25862, encryptionId=0edb25862cb, topicName=传导阻滞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98e185, createdName=psybestwish, createdTime=Thu Apr 22 11:51:46 CST 2021, time=2021-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854840, encodeId=96ac18548409b, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon May 03 04:51:46 CST 2021, time=2021-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069776, encodeId=0c6d2069e7655, content=<a href='/topic/show?id=e2628000e9f' target=_blank style='color:#2F92EE;'>#羟基氯喹#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80007, encryptionId=e2628000e9f, topicName=羟基氯喹)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2978132, createdName=minzju5052, createdTime=Tue Jul 21 20:51:46 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826616, encodeId=69b418266168c, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sun Mar 28 21:51:46 CST 2021, time=2021-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326688, encodeId=034f1326688f6, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Jul 23 02:51:46 CST 2020, time=2020-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803699, encodeId=816780369993, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4f25401928, createdName=ms8000000430368165, createdTime=Tue Jul 21 16:03:29 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803677, encodeId=1d7a8036e738, content=学到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec885401888, createdName=moira11, createdTime=Tue Jul 21 13:51:07 CST 2020, time=2020-07-21, status=1, ipAttribution=)]
    2020-07-21 moira11

    学到了

    0

相关资讯

JAHA:门诊利尿剂强化治疗会增加心衰患者死亡风险

失代偿性心力衰竭(HF)住院后死亡率增加,在此期间利尿剂通常会加重,目前尚不清楚在门诊强化利尿剂治疗心力衰竭后风险是如何影响的。

JACC:外周动脉疾病患者的他汀药使用情况

外周动脉疾病(PAD)会增加动脉粥样硬化疾病(ASCVD)的发病风险。本研究的目的是比较PAD患者与冠心病(CHD)或脑血管病患者发生ASCVD事件的风险以及他汀类药物的使用情况。

JAHA:年龄对收缩压与心血管病风险相关性的影响研究

糖尿病患者收缩压(SBP)与心血管疾病(CVD)的关系尚不清楚。本研究旨在探讨SBP与CVD之间的年龄相关性。

JAHA:PCSK9抑制剂可改善HIV携带者冠脉健康

PCSK9(前蛋白转化酶枯草杆菌素9型)因其在胆固醇代谢中的重要作用而被熟知。PCSK9水平的升高可增加心血管疾病风险,PCSK9抑制剂(PCSK9i)可以降低冠心病患者的心血管事件发生率。PCSK9

JACC:RAAS抑制剂不会增加COVID-19风险

冠状病毒病-2019(COVID-19)是由严重急性呼吸综合征冠状病毒-2引起的,冠状病毒2通过血管紧张素转换酶2与肾素-血管紧张素-醛固酮系统(RAAS)结合。这种相互作用被认为是RAAS抑制剂治疗

JACC:COVID-19大流行期间心血管病住院率明显下降

尽管心血管疾病患者面临COVID-19时患严重疾病的风险很高,但这次大流行可能对这些高危患者存在非直接的影响。本研究旨在探讨三级医疗卫生系统中急性心血管疾病住院的纵向趋势。